Govt Releases Updated List of Approved COVID-19 Vaccines in India for 2026
New Delhi: In a comprehensive update on COVID-19 immunization status, the Government of India has released the latest list of COVID-19 vaccines approved in the country as of April 22, 2026, covering vaccines permitted for manufacture, primary vaccination under restricted emergency use, and booster (third dose) administration.
The approvals have been granted under emergency use provisions, with detailed specifications on dosing schedules, age groups, storage conditions, and shelf life for each vaccine.
1. COVID-19 vaccines approved for Manufacture for Sale or for Distribution in the country
No | Vaccine | Applicant | Date of EUA | Date of approval | Age group | Dosing schedule | Route & Storage | Shelf Life as on 04.10.2022 |
1 | ChAdOx1 nCoV-19 Corona Virus Vaccine Recombinant (COVISHIELD) | M/s Serum Institute of India Pvt. Ltd. | 03.01.2021 | 27.01.2022 | ≥ 18 years | Two doses, 4 to 6 weeks apart (Overseas Data available for 12weeks) | Intramuscular, 2- 8°C | 9 months |
2 | Whole Virion Inactivated SARS-CoV- 2 Vaccine (COVAXIN) | M/s Bharat Biotech International Limited | 03.01.2021 | 27.01.2022 | ≥ 18 years | Two doses, Day 0 & 28 | Intramuscular, 2- 8°C | 12 months |
3 | SARS-CoV-2 vaccine containing Receptor Binding Domain (RBD) of SARS-CoV-2 gene (CORBEVAX) | M/s Biological E Limited | 28.12.2021 | 01.07.2025 | ≥ 12 years | Two doses, Day 0 & 28 | Intramuscular, 2- 8°C | 12 months |
4 | COVID-19 Vaccine, Adjuvanted (SARS-CoV-2 rS Protein (COVID-19) Nanoparticle Vaccine, (Omicron JN.1 Variant) with Matrix M1 adjuvant (also denoted as Matrix-M) (COVOVAX) | M/s Serum Institute of India Pvt. Ltd. | 28.12.2021 | 07.04.2026 | ≥ 12 years | Single dose | Intramuscular, 2- 8°C | 12 months |
Note: COVISHIELD, COVAXIN, CORBEVAX & COVOVAX vaccines were initially approved for Restricted Use in Emergency Situation in the country on 03.01.2021, 03.01.2021 and 28.12.2021 respectively.
- COVID-19 vaccines approved for Primary vaccination series for Restricted Use in Emergency Situation in the country
Sr. No | Vaccine | Applicant | Date of approval | Age group | Dosing schedule | Route & Storage | Shelf Life as on 04.10.2022 |
1 | Gam COVID Vac (component I & II) (SPUTNIK-V) | M/s Dr. Reddy’s Lab. Ltd. (Importer) | 12.04.2021 | ≥ 18 years | Two doses, Day 0 (comp I) & Day 21 (comp II) | Intramuscular, -18°C | 12 months |
2 | mRNA-1273COVID-19 vaccine (Moderna vaccine) | M/s Cipla Ltd. (Importer) | 29.06.2021 | ≥ 18 years | Two doses, Day 0 & 28 | Intramuscular, -25°C to -15°C | 7 months |
3 | Gam COVID Vac (component I & II) (SPUTNIK-V) | M/s Panacea Biotec Ltd | 02.07.2021 | ≥ 18 years | Two doses, Day 0 (comp I) & Day 21 (comp II) | Intramuscular, -18°C | 12 months |
4 | COVID-19 vaccine (Ad26.COV2-S) [recombinant] (Janssen Vaccine) | M/s Johnson & Johnson Pvt. Ltd. (Importer) | 07.08.2021 | ≥ 18 years | Single dose | Intramuscular, -25°C to - 15°C &2-8°C | 6 months |
5 | COVID-19 vaccine (Ad26.COV2-S) [recombinant] (Janssen Vaccine) | M/s Biological E Limited | 18.08.2021 | ≥ 18 years | Single dose | Intramuscular, -25°C to -15°C & 2-8°C | 6 months |
6 | Novel Corona Virus-2019-nCov vaccine (rDNA) (ZyCoV-D) | M/s Cadila Healthcare Limited | 20.08.2021 | ≥ 12 years | Three doses Day 0, 28 & 56 | Intradermal ,2°-8°C | 12 months |
7 | Gam COVID Vac (component I & II) (SPUTNIK-V) | M/s Hetero Biopharma Ltd | 07.10.2021 | ≥ 18 years | Two doses, Day 0 (comp I) & Day 21 (comp II) | Intramuscular, -18°C | 6 months |
Sr. No | Vaccine | Applicant | Date of approval | Age group | Dosing schedule | Route & Storage | Shelf Life as on 04.10.2022 |
8 | Whole-Virion Inactivated SARS-CoV-2 Vaccine (COVAXIN) | M/s Bharat Biotech International Limited | 24.12.2021 | ≥ 12 to 18 years | Two doses, Day 0 & 28 | Intramuscular, 2- 8°C | 12 months |
26.04.2022 | >6 to <12 years | ||||||
9 | SARS-CoV-2 vaccine containing Receptor Binding Domain (RBD) of SARS-CoV-2 gene (CORBEVAX) | M/s Biological E Limited | 26.04.2022 | ≥5 to < 12 years | Two doses, Day 0 & 28 | Intramuscular, 2- 8°C | 18 months |
10 | SARS-CoV-2 rS Protein (COVID-19) recombinant spike protein Nanoparticle Vaccine (COVOVAX) | M/s Serum Institute of India Pvt. Ltd. | 28.12.2021 | ≥ 18 years | Two doses, Day 0 & 21 | Intramuscular, 2- 8°C | 9 months |
08.03.2022 | ≥ 12 years | ||||||
28.06.2022 | ≥ 7 to < 12 years | ||||||
11 | Recombinant adenoviral vector vaccine containing particles of serotype 26 containing the protein S gene of the SARS-CoV-2 virus (SPUTNIK Light) | M/s Dr. Reddy’s Lab. Ltd. (Importer) | 05.02.2022 | ≥ 18 years | Single dose | Intramuscular, -18°C | 6 months |
12 | Recombinant adenoviral vector vaccine containing particles of serotype 26 containing the protein S gene of the SARS-CoV-2 virus (SPUTNIK Light) | M/s Hetero Biopharma Ltd | 16.03.2022 | ≥ 18 years | Single dose | Intramuscular, -18°C | 6 months |
13 | Novel Corona Virus-2019-nCov vaccine (rDNA) (ZyCoV-D) | M/s Cadila Healthcare Limited | 26.04.2022 | ≥ 12 years | Two doses, Day 0 & 28 | Intradermal, 2-8°C | 9 months |
14 | Lyophilized mRNA Vaccine for Injection (COVID-19) (HGCO-19) | M/s Gennova Biopharmaceuticals Limited | 28.06.2022 | ≥ 18 years | Two doses, Day 0 & 28 | Intramuscular, 2- 8°C | 6 months |
15 | ChAd36-SARS-CoV-S COVID-19 (Chimpanzee Adenovirus Vectored) recombinant COVID-19 Vaccine (iNCOVACC) | M/s Bharat Biotech International Limited | 06.09.2022 | ≥ 18 years | Two doses, Day 0 & 28 | Intra Nasal 2-8°C | 6 Months |
- COVID-19 vaccines approved for Booster (third) dose vaccination for Restricted Use in Emergency Situation in the country.
Sr. No | Vaccine | Applicant | Date of approval | Age group | Dosing schedule | Route & Storage |
1 | SARS-CoV-2 vaccine containing Receptor Binding Domain (RBD) of SARS-CoV-2 gene (CORBEVAX) | M/s Biological E Limited | 03.06.2022 | ≥18 years | Single dose to be administered 6 months after primary vaccination (two doses) with COVAXIN or COVISHIELD. | Intramuscular, 2- 8°C |
2 | SARS-CoV-2 rS Protein (COVID-19) recombinant spike protein Nanoparticle Vaccine (COVOVAX) | M/s Serum Institute of India Pvt. Ltd. | 16.01.2023 | ≥ 18 years | Single dose to be administered 6 months after primary vaccination (two doses) with COVAXIN or COVISHIELD. | Intramuscular, 2-8°C |
3 | Novel Corona Virus 2019-nCoV Vaccine (Recombinant) (3 mg, Single dose) (ZyCoV-D) | M/s Zydus Lifesciences Limited | 20.04.2023 | ≥ 18 years | Single dose booster (third) dose of Novel Corona Virus 2019-nCoV Vaccine (Recombinant) (3mg, Single dose) to individuals aged ≥18 years after 6 months of primary vaccination (of 2 doses) of either COVAXIN or COVISHIELD. | Intradermal, 2-8°C |
4 | ChAd36-SARS-CoV-S COVID-19 (Chimpanzee Adenovirus Vectored) recombinant COVID- 19 Vaccine (iNCOVACC) | M/s Bharat Biotech International Limited | 24.11.2022 | ≥ 18 years | To administer booster dose (third dose) after 6 months to individuals of age >18 years who have already administered primary (two doses) of COVAXIN or COVISHIELD vaccines | Intra Nasal, 2-8°C |
5 | Lyophilized mRNA Vaccine for Injection (COVID-19) (GEMCOVAC-OM) | M/s Gennova Biopharmaceuticals Ltd. | 07.07.2023 | ≥ 18 years | Single booster dose in individuals aged ≥18 years administered at least 4 months after completion of primary vaccination with either COVISHIELD or COVAXIN. | Intradermal, 2-8°C |
To view the official notice, click the link below:
